The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00125-023-05966-9.pdf
Reference101 articles.
1. Bray GA, Kim KK, Wilding JPH (2017) Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 18(7):715–723. https://doi.org/10.1111/OBR.1255110.1111/obr.12551
2. Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945):766–781. https://doi.org/10.1016/S0140-6736(14)60460-8
3. Pottegård A, Andersen JH, Søndergaard J, Thomsen RW, Vilsbøll T (2022) Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. https://doi.org/10.1111/DOM.14947
4. Andreasen CR, Andersen A, Knop FK, Vilsbøll T (2021) Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes Obes Metab 23(S3):40–52. https://doi.org/10.1111/DOM.14500
5. Frías JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503–515. https://doi.org/10.1056/nejmoa2107519
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials;Journal of Diabetes and its Complications;2024-08
2. The role of incretin receptor agonists in the treatment of obesity;Diabetes, Obesity and Metabolism;2024-07-29
3. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies;World Journal of Methodology;2024-06-20
4. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease;Hepatology International;2024-06-08
5. Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases;Alimentary Pharmacology & Therapeutics;2024-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3